STAT+: Abivax seeks to ease safety concerns with new data, boosting shares

Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.
💡 AI analysis provides alternative perspectives on current events